Today, most cancer is being found before a man turns age 70. With the help of the prostate-specific antigen (PSA) blood test and the digital rectal exam (DRE), approximately 75 percent of prostate cancer is found within the gland.
In response to earlier detection, new paradigms are emerging in prostate cancer treatments that are less invasive and better at reducing side effects. There are also new programs designed to delay or avoid treatment altogether called active surveillance or watchful waiting.
Due to the changing landscape, patients need clear, reliable information that will help their doctor make an accurate diagnosis and the right choice for treatment or management. In the prostate, fusion merges previously captured prostate MRI images with live TRUS (transrectal ultrasound) images while the ultrasound transducer is inserted during the biopsy.
Not every patient needs an MRI fusion for a biopsy. Your urologist can help you determine what is best for your individual situation.
